The Jagiellonian University in Krakow has signed a license agreement with Acatavir for the development of a product for use in veterinary medicine in the treatment and prevention of a disease called cat flu.

Viral inflammation of the upper respiratory tract, caused by feline herpesvirus type 1 (FHV-1) or by feline calicivirus (FCV), is a very common infectious disease in cats called feline rhinitis.

The disease is widely known and its viral etiological factors are well described. Treatment is based on antibiotic therapy to prevent secondary bacterial infections. However, no therapeutic agent that acts directly on FCV is currently used in veterinary medicine.

As a result of the research, scientists from the Jagiellonian University have identified a compound that is approved for use even in humans. This compound is effective against both viruses that cause cat flu.